

Notice of References Cited

Application/Control No.
09/709,170Applicant(s)/Patent Under
Reexamination
WARRELL ET AL.Examiner
Terra GibbsArt Unit
1635

Page 1 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,214,986 B1 04-2001	06-1999	Bennett et al.	536/24.5
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

Include as applicable. Author Title Date, Publisher, Edition or Volume, Pertinent Pages

*	U	Fl Raynaud et al. Journal of Pharmacology and Experimental Therapeutics," Pharmacokinetics of C3139, a Phosphorothioate Oligodeoxynucleotide... Intravenous Administration or Continuous Subcutaneous Infusion to Mice," Dec. 1996, Vol. 281, No. 1, pp. 420-427
	V	DE Lopes de Menezes et al., Clinical Cancer Res., "Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2... Rees and Liposomal Doxorubicin," Jul. 2000, Vol. 6, pp. 2891-2902
	W	H Miyake et al., Journal of the Natl. Cancer Institute, "Chemosensitization and Delayed Androgen-Independent Recurrence... Antisense Bcl-2 Oligodeoxynucleotides," Jan. 2000, Vol. 92, No. 1, pp. 34-41
	X	FE Cotter et al., Biochimica et Biophysica Acta 1419, "Human Bcl-2 antisense therapy for lymphomas," 1999, pp. 97-106

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(e))
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.